The impact of disease stage on direct medical costs of HIV management: A review of the international literature

PharmacoEconomics

Volumn 28, Issue SUPPL. 1, 2010, Pages 35-47

  Levy, Adrian ^a   Johnston, Karissa ^b   Annemans, Lieven ^c,d   Tramarin, Andrea ^e   Montaner, Julio ^f  

^a DALHOUSIE UNIVERSITY   (Canada)

^b ICON PLC   (United Kingdom)

^c GHENT UNIVERSITY   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e Ospedale Civile Di Vicenza   (Italy)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL COST; HUMAN; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; VIRUS LOAD;

EID: 78650741667     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11587430-000000000-00000     Document Type: Review

References (52)

1. Fauci AS. The AIDS epidemic - considerations for the 21st century. N Engl J Med 1999; 341: 1046-50
2. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21: 685-92
3. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-30
4. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60
5. PomerantzRJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9: 867-73
6. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-19
7. Hogan DR, Salomon JA. Prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome in resource-limited settings. Bull WHO 2005; 83: 135-43
8. European AIDS Clinical Society. European Treatment Guidelines. 2005 [online]. Available at: Http://www.eur opeanaidsclinicalsociety.org/Guidelines/ index.htm [Accessed 2010 Nov 28]
9. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 Recommendations of the International AIDS Society - USA panel. JAMA 2006; 296: 827-43
10. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIVinfected adults with antiretroviral therapy (2006). HIV Med 2006; 7: 487-503
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of Antiretroviral agents in HIV-1-infected individuals. Department of Health and Human Services; 2009:1-161 [online]. Available at: Http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf [Accessed 2010 Nov 28]
12. Hamers FF, Downs AM. The changing face of the HIV epidemic in western Europe: What are the implications for public health policies? Lancet 2004; 364: 83-94
13. Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antiviral Ther 2002; 7: 257-66
14. JointUnited Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). Joint United Nations Programme on HIV/AIDS (UNAIDS) 2010 Available at: Http://www.unaids.org/en/KnowledgeCentre [Accessed 2010 Nov 28]
15. Gardner LI, Klein RS, Szczech LA, et al. Rates and risk factors for condition-specific hospitalizations in HIVinfected and uninfected women. J Acquir Immune Defic Syndr 2003; 34: 320-30
16. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997; 11: F101-5
17. Paul S, GilbertHM, Ziecheck W, et al. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999; 13: 415-18
18. Mocroft A, Monforte A, Kirk O, et al. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med 2004; 5: 437-47
19. Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis 2006; 6: 171-7
20. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344: 817-23
21. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963-9
22. Beck EJ, Tolley K. Financing HIV service provision in England: Estimated impact of the cost of antiretroviral combination therapy. Int J STD AIDS 1998; 9: 512-17
23. Moeremans K, Annemans L, Löthgren M, et al. Cost effectiveness of darunavir/ritonavir 600/100mg bid in protease inhibitor- experienced, HIV-1-infected adults in Belgium, Italy and Sweden. PharmacoEconomics 2010; 28 Suppl. 1: 107-28
24. Caekelbergh K, Moeremans K, Annemans L, et al. Cost of care for HIV/AIDS in Belgium according to disease stage [Abstract P19.5/01]. 11th European AIDS Conference. 2007
25. Ghatnekar O, Gisslen M, Hjortsberg C, et al. Medical resource use and cost of HIV-related care in the HAART era at a university clinic in Sweden [abstract P19.10/01]. 11th European AIDS Conference. 2007
26. Organization for Economic Growth and Development. Health Data 2006. Organization for Economic Growth and Development (OECD) 2006 Accessed: 2006 Nov; Available at: Http://www.oecd.com
27. Schmid CH, Stark PC, Berlin JA, et al. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 2004; 57: 683-97
28. Hoffmann JP.Generalized linearmodels: An applied approach. Upper Saddle River, NJ, USA; Pearson Education, 2004
29. Roberts RR, Kampe LM, Hammerman M, et al. The cost of care for patients with HIV from the provider economic perspective. AIDS Patient Care and STDs 2006; 20: 876-86
30. Garattini L, Tediosi F, Di Cintio E, et al. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care- Psycholog Socio-Med Aspects AIDS/HIV 2001; 13: 733-41
31. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006; 42: 1003-10
32. Crane L, Crowe R, Fine S, et al. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr 2002; 30: 21-6
33. Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV health care in the HAART era [abstract 537]. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO. 2006
34. Drummond M, O'Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford Medical Publications, Oxford, UK, 1997
35. Kaiser Family Foundation. HIV/AIDS Fact Sheet: The HIV Epidemic in the United States. Menlo Park, CA: 2007 [online]. Available at: Www.kff.org/hivaids/ upload/3030- 103.pdf [Accessed 2010 Nov 28]
36. Tolley K, Gyldmark M. The treatment and care costs of people with HIV-infection or AIDS - development of a standardized cost framework for Europe. Health Policy 1993; 24: 55-70
37. Palmer S, Raftery J. Economic notes: Opportunity cost. BMJ 1999; 318: 1551-2
38. Beck EJ,MinersAH, TolleyK. The cost ofHIV treatment and care. A global review. PharmacoEconomics 2001; 19: 13-39
39. Hanvelt RA, Ruedy NS, Hogg RS, et al. Indirect costs of HIV/AIDS mortality in Canada. AIDS 1994; 8: F7-11
40. Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy - Evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr 2006; 43: 451-7
41. Mullins CD, Whitelaw G, Cooke SL, et al. Indirect cost of HIV infection in England. Clin Therapeut 2000; 22: 1333-45
42. Rice DP, Cooper BS. The economic value of human life. Am J Public Health Nations Health 1967; 57: 1954-66
43. Phillips AN, Lepri AC, Lampe F, et al. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 2003; 17: 1863-9
44. Richman DD. Human immunodeficiency virus. International Medical Press, London, UK, 2003
45. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-31
46. Hornberger J, Kilby JM, Wintfeld N, et al. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. AIDS Res Hum Retroviruses 2006; 22: 240-7
47. Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004; 5: 294-304
48. SimpsonKN, LuoMP, Chumney EC, et al. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral- naive patients: Modelling the combined effects of HIV and heart disease. Clin Drug Invest 2007; 27: 67-74
49. BurmanWJ, Reves RR, Cohn DL. The case for conservative management of early HIV disease. JAMA 1998; 280: 93-5
50. Holmberg SD, Palella Jr FJ, Lichtenstein KA, et al. The case for earlier treatment of HIV infection. Clin Infect Dis 2004; 39: 1699-704
51. Walker BD, Basgoz N. Treat HIV-1 infection like other infections - treat it. JAMA 1998; 280: 91-3
52. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2010 Available at: Http://www.unaids.org/en/PolicyAnd Practice/ResourcesAndFunding/default.asp [Accessed 2010 Nov 28]